Santaris Advances Two Hypercholesterolemia Rx Candidates; One Poised to Enter Clinical Trials in 2010 | GenomeWeb

By Doug Macron

Santaris Pharma last month said that it has advanced two hypercholesterolemia drug-development programs further within its preclinical pipeline, with one poised to enter human testing next year.

And while the locked nucleic acid technology upon which the drugs are based is novel, the targets are currently being pursued by at least three major RNAi and antisense firms, which could set the stage for a showdown between the three therapeutic modalities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.